Project description
New vaccine for HPV16-positive cancer tested
The EU-funded TIGER project will demonstrate the benefits of a novel mRNA cancer vaccine platform optimised for intravenous administration into patients. The antigens that will be used to deliver proof of principle comprise mRNAs encoding the proteins E6 and E7 of the human papillomavirus strain 16 (HPV16) and TriMix mRNAs that act as an adjuvant to stimulate dendritic cells to initiate strong T-cell responses. The study will be in patients with recurrent HPV16-positive cancer without and with a PD-1 checkpoint inhibitor. Safety, immunogenicity and clinical benefit will be key endpoints for this study. Once validated, the platform will be readily translatable to a wide range of cancers using other tumour antigens.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
2845 Niel
Belgium
See on map
Participants (7)
223 81 Lund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1081 HV Amsterdam
See on map
1200 Bruxelles
See on map
1000 Bruxelles
See on map
4000 Liege
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1019 HD Amsterdam
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
9880 Aalter
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.